title: [Evidence for thrombosis prophylaxis to high-risk patients].
authors.affiliation: Anders.Sjalander@LVN.se
authors.forename: Anders
authors.initials: A
authors.lastname: Själander
authors.forename: Jan-Håkan
authors.initials: JH
authors.lastname: Jansson
authors.forename: David
authors.initials: D
authors.lastname: Bergqvist
authors.forename: Henry
authors.initials: H
authors.lastname: Eriksson
authors.forename: Peter
authors.initials: P
authors.lastname: Svensson
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D013923:Thromboembolism / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight